Healthcare
Tularaemia Treatment Market

Tularaemia Treatment Market

Tularaemia Treatment Market: Global Industry Trend Analysis 2013 to 2017 and Forecast 2018 - 2028

ID: PMRREP25894

Upcoming

Introduction

Tularemia is zoonosis disease of wide variety of wild birds and mammals. Humans are infected mainly through the bite of arthropods, particularly ticks and mosquitoes. Tularemia is an infectious disease caused by the gram negative bacteria known as Francisella tularensis. Tularemia occurs mainly in North America, Europe and Asia, a few cases are acquired in Australia.

People can develop tularemia by breathing in the F. tularensis contaminated air and consuming F. tularensis contaminated drink or food or having contact with infected animals. Symptoms of Tularemia includes joints and muscle aches, shortness in breathing, and chest pain, swollen lymph glands in the neck, headache, cough, etc. diagnosis of tularemia is usually done by the series of blood tests. tularemia is mostly distributed in the Northern hemisphere and is not found in the southern hemisphere or tropics.

According to the European center for disease prevention and control, the number of human cases is approximately 800 annually. Antibiotics are usually given to the patients suffering from Tularemia. Treatment usually last for 10 to 21 days depending upon the stage and medication given. According to CDC, 230 cases of tularemia were reported in United States in 2016. Tularemia is a rare disease which is difficult to diagnose and is usually mistaken with other common illness.

Antibiotic treatment for tularemia is based on few drugs and development of novel therapeutic approaches in the recent years to improve the treatment pattern spur the market of tularemia treatment in near future. Increasing incidence of tularemia in various developed economies and developing economies significantly drive the tularemia treatment market in the forecast period.

Lack of effective and safe vaccine availability restraints the growth of tularemia. Stringent regulation for the approval of drugs is one among the restraint which hinder the growth of tularemia treatment market in near future.